Jump to content

Pubmed-Association of fructose consumption with prevalence of Functional Gastrointestinal Disorders (FGIDs) manifestations: Results from Hellenic National Nutrition and Health Survey (HNNHS)


Health Reporter

Recommended Posts

Br J Nutr. 2023 May 18:1-33. doi: 10.1017/S0007114523001198. Online ahead of print.

ABSTRACT

BACKGROUND & OBJECTIVE: The study aimed to assess the total prevalence of functional gastrointestinal disorders (FGIDs), and separately, irritable bowel syndrome (IBS) among adults and to determine their potential association with fructose consumption.

MATERIALS & METHODS: Data from the Hellenic National Nutrition and Health Survey (HNNHS) were included (3798 adults; 58.9% females). Information regarding FGID symptomatology was assessed using self-reported physician diagnosis questionnaires the reliability of which were screened using the ROME III, in a sample of the population. Fructose intake was estimated from 24 hour recalls and the MedDiet score was used to assess adherence to the Mediterranean diet.

RESULTS: The prevalence of FGID symptomatology was 20.2%, while 8.2% had IBS (representing 40.2% of total FGID). The likelihood of FGID were 28% higher (95%CI: 1.03-1.6) and of IBS 49% (95%CI: 1.08-2.05) in individuals with higher fructose intake than with lower intake (3rd tertile compared to 1st). When area of residence was accounted for, individuals residing in the Greek islands, had a significantly lower probability of FGID and IBS compared to those residing in Mainland and the main Metropolitan areas, with Islanders also achieving a higher MedDiet score and lower added sugar intake, comparatively to inhabitants of the main metropolitan areas.

CONCLUSIONS: FGID and IBS symptomatology was most prominent among individuals with higher fructose consumption, and this was most conspicuous in areas with a lower Mediterranean diet adherence, suggesting that the dietary source of fructose rather than total fructose should be examined in relation to FGID.

PMID:37197939 | DOI:10.1017/S0007114523001198

View the full article

Link to comment
Share on other sites

×
×
  • Create New...